In Southeast Asia, a region home to over 670 million people, a stark disparity in artificial intelligence (AI) investment exists. Singapore attracts a significant $68 per capita in AI investment, while the majority of other Southeast Asian nations, including populous Indonesia and Vietnam, receive less than $1 per person, according to East Asia Forum. This extreme unevenness leaves most of the region's inhabitants excluded from the foundational economic benefits and innovation opportunities that AI development promises.
Significant venture capital funds explicitly target Southeast Asia for AI and healthcare opportunities, creating a tension. However, the actual per capita investment in AI remains extremely low across most of the region. This disconnect between stated investment interest and on-the-ground capital deployment presents a critical challenge for regional development.
The current funding trends suggest that while Singapore will continue to be a dominant regional AI and biotech hub, other Southeast Asian nations risk falling further behind in technological advancement and economic growth. Targeted investment and strategic policy changes are necessary to prevent the stifling of broader regional economic development.
A Region Attracting Significant Capital
Kembangan Capital Partners (KCP) recently completed the first close of two investment vehicles, raising USD 725 million. This capital specifically targets opportunities in China, India, Japan, South Korea, and Southeast Asia, focusing on AI, healthcare, life sciences, consumer, and financial services, according to KrASIA. Such large fund closures signal a robust appetite among investors for innovative ventures across the broader Asia-Pacific, including Southeast Asia. However, the disparity in per capita investment suggests that this capital is not uniformly distributed across the region.
Singapore's Unrivaled Dominance in AI/Biotech
Around 75 percent of total AI venture capital investment in Southeast Asia is concentrated in Singapore, amounting to US$8.4 billion, states East Asia Forum. This concentration means that the 'Southeast Asia' AI market is, in practical terms, almost exclusively Singapore. In contrast, Indonesia received US$1.9 billion in AI venture capital investment, and Vietnam received just US$95 million. The extreme concentration of AI investment in Singapore creates a critical regional imbalance, potentially stifling innovation and growth in other promising markets.
Emerging Biotech and AI Applications Across the Region
OmicsBank, a health tech company, has deployed its technology across more than 90 hospitals and diagnostic laboratories in Asia, according to Pulse 2.0. Its infrastructure standardizes and de-identifies information within hospital environments, connecting clinical events with imaging and multi-omics data. OmicsBank's deployment across more than 90 hospitals and diagnostic laboratories in Asia shows that health tech innovation can still scale across the region despite centralized AI funding. Additionally, Living Roots, a Thailand-based agriculture technology company, secured seed funding from angel investors under Epic Angels for developing biological alternatives to synthetic fertilizer, as reported by KrASIA. These examples illustrate the diverse and impactful applications of biotech and AI emerging across Southeast Asia, even in less-funded ecosystems, suggesting different growth models.
The Path Forward for Regional Innovation
Based on East Asia Forum data, the extreme concentration of 75% of AI venture capital in Singapore means that most of Southeast Asia's 670 million people are being left out of the foundational economic benefits and innovation opportunities that AI development promises. The stark contrast between large funds like KCP targeting 'Southeast Asia' for AI and healthcare opportunities and the reality of less than $1 per capita AI investment in most countries suggests that investors are either struggling to find viable AI startups outside Singapore or are prioritizing established hubs, leaving vast regional potential untapped. Despite the AI investment disparity, the regional reach of biotech companies like OmicsBank, which operates across 90+ hospitals in Asia, indicates that health tech innovation can still scale across the region, potentially offering a different model for distributed growth compared to the highly centralized AI funding landscape. The current trajectory suggests a widening gap in technological advancement across Southeast Asia, necessitating strategic shifts from both investors and local governments to foster more equitable and widespread innovation. By 2026, targeted initiatives for startups in emerging markets like Vietnam and Indonesia could begin to diversify the region's innovation landscape. For more, see our Venture Capital Trends for Startups.
Frequently Asked Questions
What are the latest biotech investment trends in Southeast Asia?
Beyond the concentration in Singapore, the broader Asia-Pacific region, encompassing Southeast Asia, shows increasing investor interest in digital health and precision medicine. This focus, highlighted by Bain & Company, suggests a growing emphasis on data-driven healthcare solutions. Investors are seeking technologies that can analyze vast amounts of health data to personalize treatments and improve patient outcomes.
How is AI impacting biotech startups in SEA in 2026?
AI is primarily impacting biotech startups in Southeast Asia by enabling advanced data standardization, analysis, and clinical insights. Companies like OmicsBank use AI to process electronic health records and multi-omics data, creating robust platforms for medical research and application. This foundational AI infrastructure supports drug discovery, diagnostics, and personalized treatment plans across diverse hospital networks.
Which biotech sectors are attracting the most AI investment in 2026?
While overall AI investment is concentrated, within biotech, sectors leveraging large-scale data for diagnostics and personalized medicine are attracting significant attention. This includes areas like genomics, proteomics, and digital pathology, where AI can identify patterns and predict outcomes. These sectors promise high-impact solutions for regional health challenges and are likely to see continued growth.
